Advanced Glycation End products (AGEs), protein/glucose complexes that cross-link proteins and accumulate over time in various tissues, have been blamed for the ravages of aging as well as more specific diseases, including diabetic nephropathy. Scientists at the Fox Chase Cancer Center have discovered an enzyme pathway which leads to the formation of a precursor of AGEs. With consulting firm QED Technologies LP, which provides funding and management, the center has formed Dynamis Therapeutics Inc. , a 50-50 joint venture bent on discovering therapeutics which ultimately prevent the formation of AGEs and the diseases that they cause.
Dynamis Therapeutics Inc.
Pharmaceuticals for diabetic nephropathy
More from Archive
More from In Vivo
• By
João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.
• By
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
• By
Kevin Parker leads Cartography Biosciences in developing precision therapies for underserved cancer types, targeting proteins exclusive to tumor cells.